DocWire News Editors

DocwireNews

Researchers of a study presented at the 17th International Myeloma Workshop are aiming to characterize the longitudinal treatment pathway for patients with multiple myeloma (MM), while gaining an enhanced understanding of how long-term regimens are used.In this study, which stands as the largest prospective, non-interventional, observation, MM study to- date (INSIGHT MM), adults from 15 countries across Europe, US, Latin America, and Asia are being enrolled and followed-up with for five or more years. The researchers collected data at baseline, and subsequently accumulated more data every three months. They seek to assess duration of therapy (DoT), reasons for discontinuation, and treatments with each regimen prescribed at first-, second-, or third-line therapy.At the time of data discontinuation on Nov. 22, 2018, a total of 1,761 NDMM and 1,440 RRMM patients were enrolled, comprising 1,027 patients who had received second-line therapy, and 683 who had received third-line therapy. The regimens they evaluated included daratumumab-based therapy (lines 1/2/3, n=32/121/105), Ird (n=2/29/43), Kd (n=5/33/33), KRd (n=47/61/17), Rd (n=90/130/71), VCd (n=323/57/19), Vd (n=102/48/29), VMP (n=53/8/3), VRd (n=321/36/8), and VTd (n=200/25/4).The results showed that of 185 patients who discontinued treatment, 35% had completed planned DoT, 26% had stopped treatment due to experiencing adverse events and 14% had discontinued treatment after suffering a relapse. Among 72 patients who discontinued second-line treatment, 31% had stopped treatment due to relapse, 28% stopped due to adverse events, while 17% had completed planned DoT. Also, among third-line treatment patients, 52 discontinued treatment, and relapse was the common treatment, observed in 37% of patients, followed by 25% stopping due to adverse events, and 13% completing planned DoT.&ldquo;In this interim analysis the most common reason for stopping 1stline therapy was reaching the end of planned therapy; reasons for discontinuation change as patients move through lines of therapy,&rdquo; the researchers wrote in conclusion. &ldquo;Analyses by specific regimens and transplant status will be presented to determine impact on DoT and reasons for discontinuation.&rdquo;Weisel K, et al. A Tale of Two Paradigms: Fixed Duration vs Continuous Therapy in Routine Clinical Practice: An INSIGHT MM Study Analysis of Duration of Therapy. Presented at the 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA.

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

A Tale of Two Paradigms: Fixed Duration vs Continuous Therapy in Routine Clinical Practice: An INSIGHT MM Study Analysis

International Myeloma Workshop 2019

Researchers of a study presented at the 17th International Myeloma Workshop are aiming to characterize the longitudinal treatment pathway for patients with multiple myeloma 

A Tale of Two Paradigms: Fixed Duration vs Continuous Therapy in Routine Clinical Practice: An

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe